
|Articles|November 1, 2012
Botulinum toxin with unique makeup compares to market leader
As the popularity of botulinum toxins for both cosmetic and therapeutic applications continues to grow, so too does development of new techniques and formulations. IncobotulinumtoxinA (Xeomin, Merz), the newest of the toxin formulations, is a promising product that according to clinical studies exhibits similar efficacy to onabotulinumtoxinA (Botox, Allergan), despite having a distinctly different biological makeup.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
UCB Presents 3-Year BE HEARD Trial Results for Bimekizumab in Moderate-to-Severe HS
3
Kicking Off MOPD 2026 With Lawrence Schachner, MD
4
Sagimet and Ascletis Report Positive 52-Week Safety and Efficacy Data for Denifanstat in Acne
5











